Galera

Overview

Galera Therapeutics is discovering and developing novel mechanism-based therapies that have the potential to improve both treatment and outcomes for patients with cancer

Highlights

Raised venture capital financing to move technology into testing in patients
Successfully completed multiple clinical trials
$60M IPO in 2019 and now trading as NAS: GRTX

BioGenerator was a key early supporter of Galera and our first institutional investor. Galera capitalizes on St. Louis’ historical strengths in the discovery of truly innovative small molecule medicines.

Al Beardsley
Co-Founder & COO of Galera Therapeutics (NASDAQ: GRTX)